Literature DB >> 19010949

Temporal trends in the long term risk of progression of mild cognitive impairment: a pooled analysis.

A J Mitchell1, M Shiri-Feshki.   

Abstract

BACKGROUND: Mild cognitive impairment (MCI) is a condition that carries a substantial risk of dementia. The exact magnitude of that risk is uncertain because of the variations in the definition of MCI, the setting (such as memory clinic versus community) and, equally importantly, the duration of follow-up. Recently, a number of long term studies have been published with observation periods of 5 years of longer.
METHODS: In this quantitative review, 15 long term studies were examined and compared with the results from studies using shorter periods of observation, focusing on the annual conversion rate (ACR) of MCI to dementia.
RESULTS: The report identified six long term clinical studies conducted in specialist settings and nine long term population studies conducted in the community. Across all cohort studies with completed follow-up, the mean ACR to dementia was 4.2% (95% CI 3.9% to 4.6%). This was lower than the rate reported in studies of less than 5 years' duration. The cumulative conversion rate averaged 31.4% in this sample. The proportion converting to dementia (and Alzheimer's disease) declined with longer observation periods, suggesting that risk of progression diminishes with time.
CONCLUSION: A 10-15% ACR only appears to hold true in clinical samples monitored over a short observation period. Recruitment of older individuals from specialist centres, particularly involving those who complain of cognitive difficulties (subjective memory complaints) will tend to favour high conversion rates. In the first few years of follow-up, many of those with the most adverse risk profile will tend to progress, dropout or die, leaving a cohort of less vulnerable sufferers. However, an inverse temporal relationship was also manifest in those who completed long term follow-up, suggesting other factors are involved such as sampling issues or heterogeneity in MCI itself.

Entities:  

Mesh:

Year:  2008        PMID: 19010949     DOI: 10.1136/jnnp.2007.142679

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  35 in total

1.  Preventing cognitive decline in older African Americans with mild cognitive impairment: design and methods of a randomized clinical trial.

Authors:  Barry W Rovner; Robin J Casten; Mark T Hegel; Benjamin E Leiby
Journal:  Contemp Clin Trials       Date:  2012-03-02       Impact factor: 2.226

2.  Rate of progression from mild cognitive impairment to dementia in an essential tremor cohort: A prospective, longitudinal study.

Authors:  Keith H Radler; Maria Anna Zdrodowska; Hollie Dowd; Tess E K Cersonsky; Edward D Huey; Stephanie Cosentino; Elan D Louis
Journal:  Parkinsonism Relat Disord       Date:  2020-04-15       Impact factor: 4.891

3.  Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example.

Authors:  Jeannie-Marie S Leoutsakos; Alexandra L Bartlett; Sarah N Forrester; Constantine G Lyketsos
Journal:  Alzheimers Dement       Date:  2013-08-15       Impact factor: 21.566

4.  American Geriatrics Society and National Institute on Aging Bench-to-Bedside Conference: Sensory Impairment and Cognitive Decline in Older Adults.

Authors:  Heather E Whitson; Alice Cronin-Golomb; Karen J Cruickshanks; Grover C Gilmore; Cynthia Owsley; Jonathan E Peelle; Gregg Recanzone; Anu Sharma; Bonnielin Swenor; Kristine Yaffe; Frank R Lin
Journal:  J Am Geriatr Soc       Date:  2018-09-24       Impact factor: 5.562

5.  Neuropsychological indicators of preclinical Alzheimer's disease among depressed older adults.

Authors:  Nicole C Rushing; Natalie Sachs-Ericsson; David C Steffens
Journal:  Neuropsychol Dev Cogn B Aging Neuropsychol Cogn       Date:  2013-05-09

6.  Efficacy of akatinol memantine in moderate cognitive impairments.

Authors:  O S Levin; N A Yunishchenko; M A Dudarova
Journal:  Neurosci Behav Physiol       Date:  2010-10

Review 7.  Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).

Authors:  Ingrid Arevalo-Rodriguez; Nadja Smailagic; Marta Roqué I Figuls; Agustín Ciapponi; Erick Sanchez-Perez; Antri Giannakou; Olga L Pedraza; Xavier Bonfill Cosp; Sarah Cullum
Journal:  Cochrane Database Syst Rev       Date:  2015-03-05

Review 8.  Risk factors for the progression of mild cognitive impairment to dementia.

Authors:  Noll L Campbell; Fred Unverzagt; Michael A LaMantia; Babar A Khan; Malaz A Boustani
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

9.  Course and etiology of dysexecutive MCI in a community sample.

Authors:  Edward D Huey; Jennifer J Manly; Ming-X Tang; Nicole Schupf; Adam M Brickman; Masood Manoochehri; Jesse Mez; Charles DeCarli; Davangere P Devanand; Richard Mayeux
Journal:  Alzheimers Dement       Date:  2013-02-27       Impact factor: 21.566

10.  Are guidelines needed for the diagnosis and management of incipient Alzheimer's disease and mild cognitive impairment?

Authors:  Katie Palmer; Massimo Musicco; Carlo Caltagirone
Journal:  Int J Alzheimers Dis       Date:  2010-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.